BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Inmagene Biopharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Inmagene Biopharmaceuticals's dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07037901-1394@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olevaprubart: Phase 2 readout est. (NCT07037901)
DESCRIPTION:Olevaprubart\, phase 2\, Atopic Dermatitis.\nStudy: A Study to 
 Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Mod
 erate-to-Severe Atopic Dermatitis\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/olevaprubart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070379
 01
URL:https://assetmemo.bio/drug/olevaprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734415-1394@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olevaprubart: Phase 2 readout est. (NCT07734415)
DESCRIPTION:Olevaprubart\, phase 2\, Atopic Dermatitis.\nStudy: Long-term S
 afety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-
 Severe Atopic Dermatitis\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olevaprubart#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07734415
URL:https://assetmemo.bio/drug/olevaprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
